| Bioactivity | Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix can be used for prostate cancer research[1]. | ||||||
| Invitro | Degarelix shows only very weak histamine-releasing properties and the lowest capacity for histamine release among the antagonists of LHRH, including Cetrorelix (HY-P0009), Abarelix (HY-13534), and Ganirelix (HY-P1628)[1].Degarelix (1 nM-10 μM, 0-72 h) reduces cell viability in all prostate cell lines (WPE1-NA22, WPMY-1, BPH-1, VCaP cells), with the exception of the PC-3 cells[2].Degarelix (10 μM, 0-72 h) exerts a direct effect on prostate cell growth through apoptosis[2]. Cell Viability Assay[2] Cell Line: | ||||||
| Name | Degarelix | ||||||
| CAS | 214766-78-6 | ||||||
| Formula | C82H103ClN18O16 | ||||||
| Molar Mass | 1632.26 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Degarelix
CAS: 214766-78-6 F: C82H103ClN18O16 W: 1632.26
Degarelix is a competitive and reversible gonadotropin-releasing hormone receptor (GnRHR/LHRHR) antagonist. Degarelix ca
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.